(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Sought-After Extravagance Ocean side Objections for a Lovely Escape - 2Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know
- 3Spain breaks jobs record with 22 million Social Security contributors
- 4New York to require social media platforms to display mental health warnings
- 5People who talk with their hands seem more clear and persuasive – new research
- Manual for 6 famous sorts of cheddar
- Great DSLR Cameras for Photography Devotees
- 'Inflaming tensions': Bedouin mayor slams Ben-Gvir's unauthorized visit after meeting cancellation
- At least 7 dead as Israel renews attacks on Beirut and across Lebanon
- Google to Use Natural Gas to Power Massive Data Center in Texas
- Best Quest for new employment Site for You to Track down Amazing open doors
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Three killed as unfinished building collapses on church service in Ghana
- Artemis 2 astronauts — now halfway to the moon — report 'burning smell' from toilet, but everything's fine
